Contraceptive failure in the United States

James Trussell, James Trussell

Abstract

This review provides an update of previous estimates of first-year probabilities of contraceptive failure for all methods of contraception available in the United States. Estimates are provided of probabilities of failure during typical use (which includes both incorrect and inconsistent use) and during perfect use (correct and consistent use). The difference between these two probabilities reveals the consequences of imperfect use; it depends both on how unforgiving of imperfect use a method is and on how hard it is to use that method perfectly. These revisions reflect new research on contraceptive failure both during perfect use and during typical use.

Copyright © 2011 Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Comparing typical effectiveness of contraceptive methods

References

    1. Trussell J, Grummer-Strawn L. Contraceptive failure of the ovulation method of periodic abstinence. Fam Plann Perspect. 1990;22:65–75.
    1. World Health Organization. Comparing typical effectiveness of contraceptive methods. Geneva: World Health Organization; 2007. [cited 2010 Jun 7]. Available from: .
    1. Trussell J. Estimates of contraceptive failure from the 1995 National Survey of Family Growth. Contraception. 2008;78:85.
    1. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception. 2008;77:10–21.
    1. Arévalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. Contraception. 2002;65:333–8.
    1. Arévalo M, Jennings V, Nikula M, Sinai I. Efficacy of the new TwoDay Method of family planning. Fertil Steril. 2004;82:885–92.
    1. Frank-Herrmann P, Heil J, Gnoth C, et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod. 2007;22:1310–9.
    1. Trussell J, Strickler J, Vaughan B. Contraceptive efficacy of the diaphragm, the sponge and the cervical cap. Fam Plann Perspect. 1993;25:100–5. 135.
    1. Frezieres RG, Walsh TL, Nelson AL, Clark VA, Coulson AH. Evaluation of the efficacy of a polyurethane condom: results from a randomized controlled clinical trial. Fam Plann Perspect. 1999;31:81–7.
    1. Walsh TL, Frezieres RG, Peacock K, Nelson AL, Clark VA, Bernstein L. Evaluation of the efficacy of a nonlatex condom: results from a randomized, controlled clinical trial. Perspect Sex Reprod Health. 2003;35:79–86.
    1. Steiner MJ, Dominik R, Rountree RW, Nanda K, Dorflinger LJ. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. Obstet Gynecol. 2003;101:539–47.
    1. Farr G, Gabelnick H, Sturgen K, Dorflinger L. Contraceptive efficacy and acceptability of the female condom. Am J Public Health. 1994;84:1960–4.
    1. Raymond EG, Chen PL, Luoto J. Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial. Obstet Gynecol. 2004;103:430–9.
    1. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, editors. Contraceptive Technology: Twentieth Revised Edition. New York: Ardent Media; 2011.
    1. Grady WR, Hayward MD, Yagi J. Contraceptive failure in the United States: estimates from the 1982 National Survey of Family Growth. Fam Plann Perspect. 1986;18:200–9.
    1. Vaughan B, Trussell J, Kost K, Singh, Jones R. Discontinuation and resumption of contraceptive use: Results from the 2002 National Survey of Family Growth. Contraception. 2008;78:271–83.
    1. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect. 1999;31:64–72. 93.
    1. Trussell J, Sturgen K, Strickler J, Dominik R. Comparative contraceptive efficacy of the female condom and other barrier methods. Fam Plann Perspect. 1994;26:66–72.
    1. Farr G, Gabelnick H, Sturgen K, Dorflinger L. Contraceptive efficacy and acceptability of the female condom. Am J Public Health. 1994;84:1960–4.
    1. Ilaria G, Jacobs JL, Polsky B, et al. Detection of HIV-1 DNA sequences in pre-ejaculatory fluid. Lancet. 1992;340:1469.
    1. Pudney J, Oneta M, Mayer K, Seage G, Anderson D. Pre-ejaculatory fluid as potential vector for sexual transmission of HIV-1. Lancet. 1992;340:1470.
    1. Zukerman Z, Weiss DB, Orvieto R. Does preejaculatory penile secretion originating from Cowper’s gland contain sperm? J Assist Reprod Genet. 2003;20:157–9.
    1. Killick SR, Leary C, Trussell J, Guthrie KA. Sperm content of pre-ejaculatory fluid. Hum Fertil. in press.
    1. Preston SN. A report of a collaborative dose-response clinical study using decreasing doses of combination oral contraceptives. Contraception. 1972;6:17–35.
    1. Ledger WJ. Ortho 1557-O: a new oral contraceptive. Int J Fertil. 1970;15:88–92.
    1. Hernádi L, Marr J, Trummer D, De Leo V, Petraglia F. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception. 2009;80:18–24.
    1. Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010;81:41–48.
    1. Postlethwaite DL. Pregnancy rate of a progestogen oral contraceptive. Practitioner. 1979;222:272–5.
    1. Shroff NE, Pearce MY, Stratford ME, Wilkinson PD. Clinical experience with ethynodiol diacetate 0. 5 mg daily as an oral contraceptive. Contraception. 1987;35:121–34.
    1. Mishell DR, El-Habashy MA, Good RG, Moyer DL. Contraception with an injectable progestin. Am J Obstet Gynecol. 1968;101:1046–53.
    1. World Health Organization. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report Contraception. 1983;28:1–20.
    1. Schwallie PC, Assenzo JR. Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril. 1973;24:331–9.
    1. Scutchfield FD, Long WN, Corey B, Tyler CW. Medroxyprogesterone acetate as an injectable female contraceptive. Contraception. 1971;3:21–35.
    1. Sangi-Haghpeykar H, Poindexter AN, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88:227–33.
    1. World Health Organization. A multicentered Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: I. Contraceptive efficacy and side effects. Contraception. 1986;34:223–35.
    1. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70:269–75.
    1. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral denisty. Contraception. 2009;80:7–17.
    1. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13(Suppl 1):S4–12.
    1. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999;60:1–8.
    1. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care. 1999;4:85–93.
    1. Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M, Cedeno-Benavides T, Olvera-Porcel C, Bueno-Cavanillas A. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. Contraception. 2009;80:457–62.
    1. Yildizbas B, Sahin HG, Kolusari A, Zeteroglu S, Kamaci M. Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. Eur J Contracept Reprod Health Care. 2007;12:248–52.
    1. Gezginc K, Balci O, Karatayli R, Colakoglu MC. Contraceptive efficacy and side effects of Implanon. Eur J Contracept Reprod Health Care. 2007;12:362–5.
    1. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception. 2009;80:527–32.
    1. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 2006;74:287–9.
    1. Thamkhantho M, Jivasak-Apimas S, Angsuwathana S, Chiravacharadej G, Intawong J. One-year assessment of women receiving subdermal contraceptive implant at Siriraj Family Planning Clinic. J Med Assoc Thai. 2008;91:775–80.
    1. Agrawal A, Robinson C. An assessment of the first 3 years’ use of Implanon in Luton. J Fam Plann Reprod Health Care. 2005;31:310–2.
    1. Lipetz C, Phillips C, Fleming C. Actual cost of providing long-acting reversible contraception: a study of Implanon cost. J Fam Plann Reprod Health Care. 2009;35:75–9.
    1. Rai K, Gupta S, Cotter S. Experience with Implanon in a northeast London family planning clinic. Eur J Contracept Reprod Health Care. 2004;9:39–46.
    1. Booranabunyat S, Taneepanichskul S. Implanon use in Thai women above the age of 35 years. Contraception. 2004;69:489–91.
    1. Flores JB, Balderas ML, Bonilla MC, Vazquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet. 2005;90:228–33.
    1. Smith A, Reuter S. An assessment of the use of Implanon in three community services. J Fam Plann Reprod Health Care. 2002;28:193–6.
    1. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA. 2001;285:2347–54.
    1. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra®) on contraceptive efficacy. Contraception. 2004;69:189–95.
    1. Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005;71:176–82.
    1. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74:451–7.
    1. Sivin I, Stern J. Long-acting, more effective copper T IUDs: a summary of U.S. experience, 1970–1975. Stud Fam Plann. 1979;10:263–81.
    1. Sivin I, El Mahgoub S, McCarthy T, et al. Long-term contraception with the Levonorgestrel 20 mcg/day (LNG-IUS) and the Copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990;42:361–78.
    1. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception. 1987;36:169–79.
    1. Cox M, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report. Br J Fam Plann. 2000;26:143–7.
    1. Sivin I. Personal communication to James Trussell. Aug 13, 1992.
    1. Alderman PM. The lurking sperm: a review of failures in 8879 vasectomies performed by one physician. JAMA. 1988;259:3142–4.
    1. Moss WM. A comparison of open-end versus closed-end vasectomies: a report on 6220 cases. Contraception. 1992;46:521–5.
    1. Philp T, Guillebaud J, Budd D. Complications of vasectomy: review of 16,000 patients. Br J Urol. 1984;56:745–8.
    1. Margaret Pyke Centre. One thousand vasectomies. Br Med J. 1973;4:216–21.
    1. Kase S, Goldfarb M. Office vasectomy review of 500 cases. Urology. 1973;1:60–2.
    1. Klapproth HJ, Young IS. Vasectomy, vas ligation and vas occlusion. Urology. 1973;1:292–300.
    1. Schmidt SS. Vasectomy. JAMA. 1988;259:3176.
    1. Marshall S, Lyon RP. Variability of sperm disappearance from the ejaculate after vasectomy. J Urol. 1972;107:815–7.
    1. Jamieson DJ, Costello C, Trussell J, Hillis SD, Marchbanks PA, Peterson HB US Collaborative Review of Sterilization Working Group. The risk of pregnancy after vasectomy. Obstet Gynecol. 2004;103:848–50. Erratum in: Obstet Gynecol 2004;104:200.
    1. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996;174:1161–70.
    1. Kennedy KI, Rivera R, McNeilly AS. Consensus statement on the use of breastfeeding as a family planning method. Contraception. 1989;39:477–96.
    1. Kennedy KI, Labbok MH, Van Look PFA. Lactational amenorrhea method for family planning. Int J Gynaecol Obstet. 1996;54:55–7.
    1. Kazi A, Kennedy KI, Visness CM, Khan T. Effectiveness of the lactational amenorrhea method in Pakistan. Fertil Steril. 1995;64:717–23.
    1. Labbok MH, Hight-Laukaran V, Peterson AE, Fletcher V, von Hertzen H, Van Look PFA. Multicenter study of the lactational amenorrhea method (LAM): I. Efficacy, duration, and implications for clinical application. Contraception. 1997;55:327–36.
    1. Pérez A, Labbok MH, Queenan JT. Clinical study of the lactational amenorrhoea method for family planning. Lancet. 1992;339:968–70.
    1. Ramos R, Kennedy KI, Visness CM. Effectiveness of lactational amenorrhea in prevention of pregnancy in Manila, the Philippines: non-comparative prospective trial. Br Med J. 1996;313:909–12.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다